Interaction of cyclosporine A and the renin-angiotensin system; new perspectives

Area of Science:

• Nephrology
• Pharmacology
• Immunology

Background:

• Cyclosporine A (CsA) is widely used but associated with hypertension and nephrotoxicity.
• The precise mechanisms underlying CsA-induced renal dysfunction, particularly its interaction with the renin-angiotensin system (RAS), remain debated.
• Existing research presents conflicting data regarding CsA's impact on RAS activation in both animal models and human studies.

Purpose of the Study:

• To explore the multifaceted interactions between Cyclosporine A and the renin-angiotensin system in the context of hypertension and nephrotoxicity.
• To reconcile controversial findings on CsA's role in RAS activation and its consequences for renal health.
• To investigate potential therapeutic strategies targeting RAS for managing CsA-induced renal complications.

Main Methods:

• Review and synthesis of existing research on CsA's effects on RAS components, including renin release and angiotensin II.
• Analysis of studies examining CsA in animal models, such as rats, and clinical investigations in human subjects.
• Evaluation of data on CsA's anti-inflammatory properties, including its effects on interleukin-6 and inducible nitric oxide synthase (iNOS) expression.

Main Results:

• CsA consistently activates the RAS in rat models, potentially contributing to glomerular ischemia via vasoconstriction.
• Clinical studies present controversial findings on CsA-induced RAS activation.
• CsA demonstrated protective effects against RAS over-expression-induced renal damage in transgenic rats, attributed to its anti-inflammatory actions (inhibition of IL-6 and iNOS).
• CsA's inhibitory effect on iNOS has been confirmed in other studies.

Conclusions:

• The interaction between CsA and RAS is complex and controversial, with evidence for both activation and protective anti-inflammatory effects.
• While calcium antagonists are considered for CsA-induced hypertension, targeting the RAS may offer additional benefits for structural renal damage.
• Further research is needed to fully elucidate CsA's dual role in renal pathophysiology and optimize therapeutic interventions.